Complex of N-terminal FLAG-tagged recombinant full-length human p110β (GenBank Accession No. NM_006219), and untagged, recombinant full length, human p85α. (GenBank Accession No. NM_181523). Coexpressed in a Baculovirus infected Sf9 cell expression system. p110β MW=124 kDa, p85α MW=84 kDa.

PIK3CB, p110beta, Phosphoinositide-3-Kinase, Catalytic, Beta, PIK3R1, Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha), GRB1, p85alpha

1023 pmol/min/μg

A unit of p110β/p85α kinase activity is defined as the amount of enzyme required to produce 1 pmol of Phosphoinositol-3,4,5-Trisphosphate/min at 30°C.

A 25 μl kinase reaction is conducted in a buffer containing 40 mM Tris-HCl (pH 7.4), 20 mM MgCl₂, 100 uM ATP, 200 μM PI:PS substrate (BPS catalog #40560) and 110β/p85α enzyme for 15 minutes at 30°C. ATP reduction is detected using ADP-Glo™ Kinase Assay Platform (Promega Corporation, Madison, WI).

25 mM Tris, pH 8.0, 69 mM NaCl, 1.35 mM KCl, 0.025% Tween-20, 3 mM DTT, 50% glycerol, and 0.05 mg/ml FLAG peptide.

Aqueous buffer solution

>6 months at –80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Marques M. et al., (2008). Mol. Cell. Biol. 28 (8), 2803-2814.
2. Straub A. et al., (2008). Thromb. Haemost. 99 (3), 609-615.

Avoid freeze/thaw cycles

Kinase/Lipids

Recombinant Protein